Synovial tissue response to treatment in Psoriatic arthritis

Open Rheumatology Journal

Volumn 5, Issue SPEC. ISSUE 1, 2011, Pages 133-137

  Codullo, Veronica ^a,b   McInnes, Iain B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Biologic therapy; Biomarker; Psoriatic arthritis; Synovial tissue

Indexed keywords

ADALIMUMAB; ALEFACEPT; CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; COLLAGENASE 3; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; FLUDARABINE; GLYCOPROTEIN P 15095; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 10; STROMELYSIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; JOINT BIOPSY; KERATINOCYTE; LOW DRUG DOSE; LYMPHANGIOGENESIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAST CELL; NATURAL KILLER CELL; NEOVASCULARIZATION (PATHOLOGY); PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SKIN DISEASE; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84855835225     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901105010133     Document Type: Article

References (39)

1. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.
2. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
3. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868-72.
4. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008; 26: S62-5.
5. Bresnihan B, Baeten D, Firestein GS, et al. Synovial tissue analysis in clinical trials. J Rheumatol 2005; 32: 2481-4.
6. Gerlag D, Tak PP. Novel approaches to the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol 2008; 22: 311-23.
7. Gerlag D, Tak PP. How to perform and analyse synovial biopsies. Best Pract Res Clin Rheumatol 2009; 23: 221-32.
8. Rihl M, Baeten D, Seta N, et al. Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondyloarthropathy. Ann Rheum Dis 2004; 63: 498-507.
9. Smith MD, Baeten D, Ulfgren AK, et al. OMERACT Synovial Special Interests Group. Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go? Ann Rheum Dis 2006; 65: 93-100.
10. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7: R569-80.
11. Kruithof E, De Rycke L, Roth J, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005; 52: 3898-909.
12. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000; 43: 1244-56.
13. Boyle DL, Kavanaugh A. The pathobiology of psoriatic synovium. Curr Opin Rheumatol 2008; 20: 404-7.
14. Fransen J, Antoni C, Mease PJ, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006; 65: 1373-8.
15. Kane D, Gogarty M, O'leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004; 50: 3286-95.
16. Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 834-8.
17. Curran SA, FitzGerald OM, Costello PJ, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004; 172: 1935-44.
18. Costello PJ, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001; 166: 2878-86.
19. Takada K, Danning CL, Kuroiwa T, et al. Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects. Ann Rheum Dis 2003; 62: 1112-5.
20. Baeten D, Houbiers J, Kruithof E, et al. Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 990-7.
21. van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65: 1551-7.
22. Baeten D, Kruithof E, Van den Bosch F, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001; 44: 186-95.
23. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004; 6: R326-34.
24. Cañete JD, Pablos JL, Sanmartí R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004; 50: 1636-41.
25. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48: 2155-62.
26. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004; 63: 769-73.
27. van Kuijk AW, Gerlag DM, Vos K, et al. A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis 2009; 68: 1303-9.
28. Cañete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007; 66: 720-6.
29. Cañete JD, Celis R, Moll C, et al. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 751-6.
30. McInnes IB, Illei GG, Danning CL, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001; 167: 4075-82.
31. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002; 46: 2776-84.
32. Cañete JD, Celis R, Hernandez V, Pablos JL, Sanmartí R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory pasoriatic arthritis. Ann Rheum Dis 2010; 69: 935-6.
33. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-75.
34. Tassiulas I, Duncan SR, Centola M, Theofilopoulos AN, Boumpas DT. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999; 60: 479-91.
35. Malaviya R, Sun Y, Tan JK, et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2006; 55: 590-7.
36. Jongbloed SL, Lebre MC, Fraser AR, et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther 2006; 8: R15.
37. Lebre MC, Jongbloed SL, Tas SW, Smeets TJ, McInnes IB, Tak PP. Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine profiles. Am J Pathol 2008; 172: 940-50.
38. Jongbloed SL, Benson RA, Nickdel MB, Garside P, McInnes IB, Brewer JM. Plasmacytoid dendritic cells regulate breach of selftolerance in autoimmune arthritis. J Immunol 2009; 182: 963-8.
39. Sugita K, Hino R, Ogata M, Kabashima K, Tokura Y. Fluctuation of circulating plasmacytoid dendritic cells in a patient with psoriatic arthritis. J Eur Acad Dermatol Venereol 2008; 22: 1365-6.